PDX Portal

Model Details

Patient Information for Model: BCM-PDAC-29

Model Contact

Model: BCM-PDAC-29
Model Contact: Qizhi Cathy Yao
Institution: BCM Pancreas PDX Program
Email: qizhiyao@bcm.edu

Patient Information

Clinical Timeline

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: BCM-PDAC-29

Model Details - Initial Implantation of Patient Tissue

Mutations (Cancer Gene Census List)

Mutation data is currently not available.

CNV

Histology Information for Model: BCM-PDAC-29

There are no histology images for this model.

Metastasis Information for Model: BCM-PDAC-29

Patient

PDX

Liver

Local

Local recurrence

Lung

Rectum

lymph node

Patient Treatment Information for Model: BCM-PDAC-29

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Reason Stopped
10	Gemcitabine/capecitabine	Adjuvant	65.61	65.92	113 days	Complete Response (CR); "No evidence of disease"	Completed regimen
15	chemo/radiation	Adjuvant	66.03	66.13	36 days	Complete Response (CR); "No evidence of disease"	Completed regimen
20	Gemcitabine/Abraxane	Adjuvant	67.17	67.23	22 days		Stopped due to side effects
25	Gemcitabine	Adjuvant	67.34	67.38	15 days	Progressive Disease (PD)	Stopped due to disease progression
30	Gemcitabine/Capecitabine	Adjuvant	67.44	67.67	84 days	Unknown	Completed regimen